Kiniksa Pharmaceuticals (Kiniksa Pharmaceuticals) Change In Receivables : $-8.6 Mil (TTM As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Kiniksa Pharmaceuticals Change In Receivables?

Kiniksa Pharmaceuticals's change in receivables for the quarter that ended in Mar. 2024 was $5.3 Mil. It means Kiniksa Pharmaceuticals's Accounts Receivable declined by $5.3 Mil from Dec. 2023 to Mar. 2024 .

Kiniksa Pharmaceuticals's change in receivables for the fiscal year that ended in Dec. 2023 was $-1.0 Mil. It means Kiniksa Pharmaceuticals's Accounts Receivable increased by $1.0 Mil from Dec. 2022 to Dec. 2023 .

Kiniksa Pharmaceuticals's Accounts Receivable for the quarter that ended in Mar. 2024 was $16.0 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Kiniksa Pharmaceuticals's Days Sales Outstanding for the three months ended in Mar. 2024 was 18.28.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Kiniksa Pharmaceuticals's liquidation value for the three months ended in Mar. 2024 was $151.4 Mil.

Kiniksa Pharmaceuticals Change In Receivables Historical Data

The historical data trend for Kiniksa Pharmaceuticals's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kiniksa Pharmaceuticals Change In Receivables Chart

Kiniksa Pharmaceuticals Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

Get a 7-Day Free Trial

-3.91

-16.33

-0.95

Kiniksa Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Receivables	Get a 7-Day Free Trial															12.89	-17.23	21.61	-18.23	5.27

Kiniksa Pharmaceuticals Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-8.6 Mil.

Kiniksa Pharmaceuticals (NAS:KNSA) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Kiniksa Pharmaceuticals's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	15.995	/	79.858	*	91
=	18.28

2. In Ben Graham's calculation of liquidation value, Kiniksa Pharmaceuticals's accounts receivable are only considered to be worth 75% of book value:

Kiniksa Pharmaceuticals's liquidation value for the quarter that ended in Mar. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	213.552	-	87.778	+	0.75 * 15.995	+	0.5 * 27.278
=	151.4

Kiniksa Pharmaceuticals Change In Receivables Related Terms

Thank you for viewing the detailed overview of Kiniksa Pharmaceuticals's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Kiniksa Pharmaceuticals (Kiniksa Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kiniksa Pharmaceuticals Ltd (NAS:KNSA) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

2 Church Street, Clarendon House, Hamilton, BMU, HM11

Website

https://www.kiniksa.com

Kiniksa Pharmaceuticals Ltd is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, for the treatment of recurrent pericarditis, a debilitating inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody for the treatment of giant cell arteritis; Vixarelimab; and KPL-404.

Executives

Michael R Megna	officer: Chief Accounting Officer	1050 HINGHAM STREET, ROCKLAND MA 02370
John Paolini	officer: Chief Medical Officer	C/O KINIKSA PHARMACEUTICALS, LTD., CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11
Barry D Quart	director	C/O INTRABIOTICS PHARMACEUTICALS INC, 1009 OAK HILL ROAD, SUITE 201, LAFAYETTE CA 94549
Felix Baker	director	BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014
Baker Bros. Advisors Lp	director	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Baker Brothers Life Sciences Lp	director	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
L.p. 667,	director	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Baker Bros. Advisors (gp) Llc	director	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Julian Baker	director	BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014
Eben Tessari	officer: Chief Business Officer	C/O KINIKSA PHARMACEUTICALS LTD., CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11
Arian Pano	officer: Chief Clinical Dev. Officer	C/O KINIKSA PHARMACEUTICALS LTD., CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11
Ross Moat	officer: Group VP & Rilonacept GM	C/O KINIKSA PHARMACEUTICALS LTD., CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11
Sanj K Patel	director, 10 percent owner, officer: Chairman & CEO	C/O KINIKSA PHARMACEUTICALS, LTD., CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11
Thomas W. Beetham	10 percent owner, officer: Chief Legal Officer	C/O KINIKSA PHARMACEUTICALS, LTD., CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11
Mark Ragosa	officer: Interim CFO	C/O KINIKSA PHARMACEUTICALS CORP., 100 HAYDEN AVENUE, LEXINGTON MA 02421